Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the double-blind, U.S. Phase IIb SAPPHIRE and SILVER trials, 210 mg/day of ALT-711 failed to reduce systolic hypertension compared to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury